Kodiak Sciences Inc.
$43.26+5.3%YTD+55.0%1Y+736.8%
Mentions · last 7 days
350%
Price updated 49m ago·X counts updated 1d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $KOD, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $KOD.
Biotechnology
No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.
What this means for $KOD
Partial — Develops novel bispecific anti-VEGF antibodies for retinal diseases including wet AMD and diabetic macular edema; exposure exists but is diluted by diverse end markets and revenue mix.
Top industry ETF
$IBBiShares Biotechnology ETF
+11.2%YTD
+43.1%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-8.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-87.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-9.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-254%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.94$-0.93-1.1%
Q4 2025Mar 31, 2026$-1.04$-1.02-2.0%
Q3 2025Nov 13, 2025$-1.16$-1.07-8.4%
Q2 2025Aug 13, 2025$-1.03$-1.01-2.0%
Next earningsWed, Aug 12·consensus EPS $-0.98
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.94$-41.0M
Q4 FY25$0———$-1.04$-39.4M
Q3 FY25$0———$-1.16$-32.9M
Q2 FY25$0———$-1.03$-34.8M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$11.3M$4.5M – $16.4M-$3.74-$4.16 – -$3.354
FY27$45.9M$916K – $79.9M-$3.12-$3.53 – -$2.724
FY28$236.3M$236.3M – $236.3M-$0.86-$1.74 – -$0.393
FY29$497.9M$199.9M – $720.7M$1.17$0.26 – $1.842
FY30$870.8M$349.6M – $1.3B$4.00$0.89 – $6.331
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.85%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+10.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+44.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KShareholder voteJun 48-K — Item 5.07: Shareholder vote
AI summary
+ 14 other (5 13Gs · 2 earnings 8-Ks · 2 proxys · 1 10-Q) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Kodiak Sciences: Clinical Redemption Is Turning Into Platform LeverageKodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should KnowKodiak Stock Rises 35% in 3 Months: Here's What You Need to KnowKodiak Sciences to Present at 2026 Jefferies Global Healthcare ConferenceWhy One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 2 · last 7 days